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Clinical Observations 
Safety of Individual Medication of Ma Qian Zi (Semen Strychni) Based 
upon Assessment of Therapeutic Effects of Guo’s Therapy Against 
Moderate Fluorosis of Bone 
KONG Huan-yu ᄨ⛩ᅛ 1, ZHOU Wei ਼ि 1, GUO Pei-hua 䛁෍ढ 2, SANG Zhi-cheng ḥᖫ៤ 1,  
WU Guan-nan ਈݴ⬋ 1, CHEN Yan-jun 䰜➩ݯ 3, ZHANG Zhao-jie ᓴܚᵄ 1, and WANG Hui-ming ⥟ᚴᯢ 1 
Objective: To assess the safety of individual medication of Guo’s Ma Qian Decoction on the basis of effective 
treatment of fluorosis of bone with Guo’s therapy. 
Methods: One hundred and fourteen cases of moderate fluorosis of bone were randomly divided into a treatment 
group (n=60) and a control group (n=54) between December 2007 and August 2009 by using the block randomized 
method and a central random system. At the same time of basic treatment, the patients in the treatment group were 
orally administrated with Guo’s Ma Qian Decoction. The initial dose of Ma Qian Zi (Semen Strychni) was 0.4 g 
and increased by 0.05 g every two days, with the doses of other drugs unchanged, until the patient had “nux vomica 
response”. For the patients with no “nux vomica response”, the dosage was continued to increase and the maximum 
dosage was not more than 1.2 g/day. The control group was treated with decoction placebo. The changes of 
strychnine and brucine contents before and after processing and after decoction of Ma Qian Zi (Semen Strychni) 
were determined with reversed-phase high-performance liquid chromatography, which were controlled within 
ranges stipulated in the Pharmacopeia; Adverse events were analyzed; Blood strychnine and brucine contents in 10 
cases who had taken the drugs were determined.  
Results: 1) Strychnine (2.125%) and brucine (1.425%) contents before processing of Ma Qian Zi and 1.88% and 
1.31% after processing all conformed with the standards of strychnine (1.2–2.2%) and brucine (no less than 0.8%) 
stipulated in the Pharmacopeia. When the maximum dosage of Ma Qian Zi was 1.2 g/day, strychnine in the 
decoction was 11.17 mg and brucine was 7.44 mg, which all conformed with the maximum limited amount 
(strychnine 13.32 and brucine no less than 4.8 mg) stipulated in the Pharmacopeia. 2) Eight cases had “nux vomica 
response” in the treatment group and one case in the control group, with a significant difference between the two 
groups (P<0.05). 3) Altogether 18 cases had adverse events, with an incidence rate of 15.38% (8 cases) in the 
treatment group and 18.52% (10 cases) in the control group, with no difference between the two groups (P>0.05); 
Among them, 10 cases (8.77%) with the adverse event were not related with therapeutic drugs, with an incidence 
rate of 6.67% (4 cases) in the treatment and 11.11% (6 cases) in the control group, with no significant difference 
between the two groups (P>0.05). Seven cases had suspicious relative adverse events, the risk in the treatment 
group was 0.658 times of the control group, with no significant difference (P>0.05), and one case had the toxic 
reaction of nux-vomica seed. 4) Strychnine and brucine were unable to be detected in the blood in all points of time 
in the 10 cases who had taken the drugs, indicating that plasma strychnine and brucine contents were lower than the 
minimum detectable amount (10 ng), and accumulation of strychnine and brucine were not found in blood of the 
patient during and after administration for 8 weeks.  
Conclusion: The individual medication of Ma Qian Zi (Semen Strychni) in the Guo’s therapy has a better safety. 
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“Guo’s therapy” has been stated to improve the 
symptoms of moderate endemic fluorosis of bone.1–4
Guo’s Ma Qian Decoction is one of main therapies for 
this disease. In Guo’s Ma Qian Decoction, prepared Ma 
Qian Zi (Semen Strychni) was used as the monarch drug. 
A dose of 0.4–1.2 g, regulated according to the reaction 
caused by the treatment, has a therapeutic effect. The 
clinical dosage of Ma Qian Zi (Semen Strychni)5 has 
been strictly limited in the Chinese Pharmacopeia. In 
clinical studies using Ma Qian Zi, the dosages used were 
within the dose stipulated in the Chinese 
Pharmacopeia.6–11 However, clinical reports focusing on 
 the dosage of individual medications combined with 
safety assessment are lacking. In the present study, the 
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safety of Ma Quan Zi individual medication in Guo’s Ma 
Quan Decoction was studied based on the research of 
Guo’s therapy for moderate endemic fluorosis of bone. 
METHODS
Clinical Data and Grouping 
One-hundred and twenty cases of moderate endemic 
fluorosis of bone confirmed by clinical means in the 
Xinzhou region of Shanxi Province from December 2007 
to August 2009 were randomly divided into a treatment 
group and a control group. This was done using a block 
random method and a central random system (Clinical 
Research Data Collection and Management System of 
the Affiliated Hospital of Nanjing University of Chinese 
Medicine). At the end of the treatment, 6 cases were 
excluded from the study, leaving a study population of 
114 cases (56 male and 58 female). In the treatment 
group, 26 cases were male and 34 cases were female (age 
range, 39–60 years; mean age, 51.68±4.98 years). In the 
control group, 30 cases were male and 24 cases were 
female (39–60 years; 52.15±4.68 years).  
Diagnostic and Exclusion Criteria  
The diagnostic criteria and scale criteria for endemic 
fluorine poisoning in “Medical Profession Criteria of The 
People’s Republic of China (WS 192-2008)”12 were 
used. 
The exclusion criteria are referred to in the literature.1
Twelve exclusion criteria were used: (i) subjects with 
osteoarthritis, rheumatic arthritis, ankylosing spondylitis, 
or rheumatoid arthritis; (ii) pregnant and breastfeeding 
women; (iii) subjects with mental disorders; (iv) patients 
with a history of allergic reactions to Ma Qian Zi (Semen 
Strychni); (v) individuals who had taken drugs related to 
skeletal or dental fluorosis within the previous month, 
such as non-steroidal anti-inflammatory drugs, cortical 
hormones or Chinese drugs containing Ma Qian Zi 
(Semen Strychni); (vi) subjects with severe disease of the 
heart, liver, lung, kidney; blood-based diseases, cancer or 
AIDS; (vii) individuals with abnormal renal function; 
(viii) subjects with alanine aminotransferase (ALT) 
levels twice the upper limit of normal values; (viii) 
abnormal and clinically significant electrocardiogram; (x) 
chest radiograph indicating infection, tuberculosis or 
tumor; (xi) subjects living in an area in which the 
fluorine content in water was > 3.9 mg/L; and (xii)
individuals participating in clinical trials of other drugs. 
Individual Treatment Methods 
Simultaneously with basic treatment, patients in the 
treatment group were orally administrated Guo’s Ma 
Qian Decoction1 (Shanxi Xinzhou Pharmaceutical Group) 
twice (200 mL each time) for 8 consecutive weeks. The 
initial dose of Ma Qian Zi (Semen Strychni) was 0.4 g 
and was increased by 0.05 g every 2 days. The maximum 
dose was 1.2 g/day (the doses of other drugs were kept 
unchanged) until the patient had a “nux-vomica 
response”: slight sweating, tongue rigidity, girdle 
sensation, and slight muscular twitch. At this time, the 
dose of Ma Qian Zi (Semen Strychni) in the decoction 
was left unchanged or reduced by 0.05 g until 
disappearance of a nux-vomica response: this was the 
treatment maintenance dose of Ma Qian Zi (Semen 
Strychni) in Guo’s Ma Qian decoction. The next day, 
Guo’s Ma Qian Decoction containing the treatment 
maintenance dose of Ma Qian Zi (Semen Strychni) 
started to be used. For patients in whom the nux-vomica 
response did not appear, the dose was increased 
day-by-day until 1.2 g/day according to the method 
described above. Patients in the control group were 
administered decoction placebo. After taking Guo’s Ma 
Qian Decoction for 8 weeks, patients in the two groups 
were administered with Gu Kang Ning Jiao Nang 
(Capsules for Healthy Bone1, Shanxi Province Heruida 
Pharmaceutical Co. Ltd., batch number JZ20070024) and 
a placebo capsule, respectively. 
Observations 
1. Strychnine contents before and after Ma Qian Zi 
(Semen Strychni) processing and in the decoction
Ma Qian Zi (Semen Strychni) was purchased once only
and was supplied by the Shanxi Province Xinzhou City 
Special Hospital of Fluorosis (Xinzhou, Shanxi, China, 
batch number 070512). The brucine and strychnine 
contents in crude Ma Qian Zi (Semen Strychni), in 
prepared Ma Qian Zi, and in the Guo’s Ma Qian 
Decoction, were determined according to the methods 
described in the Chinese Pharmacopeia.13
2. Nux-vomica response 
Responses related to the treatment maintenance dose
(slight sweating, tongue rigidity, girdle sensation, slight 
muscular twitch) were investigated. 
3. Classification of adverse events 
All adverse events (abnormal laboratory results, adverse 
clinical events, toxic reactions to Ma Qian Zi (Semen 
Strychni)) were recorded. The correlation between the 
drug and adverse events was based on five classifications: 
positive correlation; very possible correlation; possible 
correlation; suspicious correlation; and impossible 
correlation. 
4. Blood contents of alkaloids of Ma Quan Zi (Semen 
Strychni) 
High-performance liquid chromatography (HPLC) 
analyses showed a linear relationship (regression 
equation for strychnine: Y=4.8835+1.1708X, r=0.9962; 
brucine: Y=6.1819+1.4085X, r=0.9937). The rate of 
recovery (n=12) for strychnine was 91.0% (relative 
standard deviation (RSD) 4%), and for brucine was 
91.63% (RSD 4.47%). The intra-day precision for 
strychnine was RSD 3.53% and for brucine was RSD 
5.21%); The stability of strychnine was RSD 3.96%, and 
fro brucine was RSD 5.70%. To determine the detection 
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method of the blood content of Ma Qian Zi (Semen 
Strychni), the lowest detectable amount was 5.0 ng and 
the quantitative limitation was 10 ng. 
The blood in 10 cases (5 males and 5 females) 
administered the decoction was taken before 
administration as well as 15 min after administration in 
the first, second, third, fourth and eighth weeks after 
administration. Samples (100 μL) were prepared 
according to the detection method for the blood content 
of Ma Qian Zi (Semen Strychni). 
5. Statistical analyses 
Descriptive statistical methods were adopted using SAS 
6.12 software (SAS, Raleigh, NC, USA). Adverse events 
in the two groups were compared using the Ȥ2 test 
(two-sided). P<0.05 was considered significant. 
Evaluation of the relative risk (RR) of abnormal 
laboratory values after treatment was also carried out. 
RESULTS 
Contents of Alkaloids in Ma Qian Zi and Ma Qian 
Decoction 
According to the China Pharmacopeia (2005 edition)5, 
strychnine content in crude Ma Qian Zi was 
1.20%–2.20%, and brucine content was not less than 
0.80%. HPLC results indicated that strychnine content 
(2.125%) and brucine content (1.425%) in crude Ma 
Qian Zi were in accordance with the values in the 
Chinese Pharmacopeia (Table 1). 
Table 1. Contents of alkaloids in crude Ma Qian Zi 
After processing of Ma Qian Zi, strychnine content 
(1.88%) and brucine content (1.31%) detected by HPLC 
were in accordance with the values in the Chinese 
Pharmacopeia (Table 2). 
When the prepared Ma Qian Zi in Guo’s Ma Qian 
Decoction was increased by 0.4, 0.6, 0.8, 1.0, and 1.2 
g/day dose in order, and at the maximum added amount 
of 1.2 g, the strychnine content was 11.17 mg and the 
brucine content was 7.44 mg. These values were in 
accordance with the maximum amount stipulated in the 
Chinese Pharmacopeia (after calculation, when the 
prepared Ma Qian Zi was 0.6 g, the amount of strychnine 
was 13.32 mg and that of brucine was not less than 4.8 
mg, Table 2). 
Table 2. Comparison of alkaloid contents in Guo’s Ma Qian Decoction and single Ma Qian Zi  
Contents of alkaloids 
Value stated in 
the Chinese Pharmacopeia (mg)
Detected value of prepared Ma 
Qian Zi (mg) 
Guo’s Ma Qian Decoction (mg) 
Prepared 
Ma Qian 
Zi  
(dosage/ 
day) 
Strychnine 
(upper limit, 
2.2%) 
Brucine 
(not less than 0.8%) 
Strychnine 
(1.88%) 
Brucine 
(1.31%) 
Strychnine 
(corresponding to 
raw drug, %) 
Brucine 
(Corresponding to 
raw drug, %) 
0.4 8.80 3.20 7.52 5.24 3.82 (50.80) 2.02 (38.55) 
0.61  13.321  4.801  11.28 7.86 5.97 (52.93) 2.53 (32.19) 
0.8 17.76 6.40 15.04 10.48 7.82 (51.99) 4.68 (44.66) 
1.0 22.20 8.00 18.80 13.10 10.03 (53.35) 6.37 (48.63) 
1.22 26.64 9.60 22.56 15.72 11.172 (49.51) 7.442 (47.33) 
Notes: 1. The theoretical value calculated according to the Chinese Pharmacopeia (2005 edition), when the upper limit was used (strychnine 
2.2%; brucine was not less than 0.8%); 2. The contents of alkaloids when the maximum dosage (1.2 g/day) of prepared Ma Qian Zi was used. 
Nux-vomica Response 
The prevalence of the nux-vomica response was 13.33% 
(8 cases) in the treatment group and 1.85% (1 case) in 
the control group: this difference was significant (P<0.05) 
(Table 3). 
Adverse Events 
Of the 114 cases, 18 cases (15.38%) had clinically 
observed adverse events. The prevalence of adverse 
events was 15.38% (8 cases) in the treatment group and 
18.52% (10 cases) in the control group: this difference 
was not significant (P>0.05, Table 4). 
Of the 18 cases with adverse events, 10 cases (8.77%) 
were not related to treatment. Among them, 4 cases 
(6.67%) in the treatment group and 6 cases (11.11%) in 
the control group were not related to treatment; this 
difference was not significant (P>0.05, Table 5). 
Table 3. Comparison of the prevalence of a nux-vomica 
response between the two groups 
Response cases 
(n) 
Group 
Yes  No 
Total cases 
(n) 
Prevalence 
(%) 
Treatment 8 52 60 13.33 
Control 1 53 54 1.85 
Total 9 105 114 7.89 
Notes: Ȥ2 value (continuity correction)=5.152, P=0.023<0.05. 
Table 4. Comparison of the prevalence of adverse events 
between the two groups 
Notes: Ȥ2 value (Pearson chi-square)=0.575, P=0.448>0.05. 
Batch No. No.  Strychnine (%) Brucine (%)
1  2.13 1 .43  070512 
2  2.12 1 .42  
Mean 2.125 1.425 
Adverse events 
cases (n) 
Group 
Yes No 
Total cases 
(n) 
Prevalen
ce (%) 
Treatment 8 52 60 15.38 
Control 10 44 54 18.52 
Total 18 96 114 15.79 
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In the treatment of moderate fluorosis of bone with 
Guo’s therapy, electrocardiography (ECG), blood, urine, 
as well as functions of the liver and kidney were 
examined. Most of these parameters had no significantly 
different abnormal changes in the two groups before and 
after treatment (Table 6). Only 7 cases had abnormal red 
blood cells (RBCs) in urine which, after causality 
analyses, was found to be weakly related to treatment. 
The risk of abnormal RBCs in urine in the treatment 
group was 0.658-times that in the control group (total RR 
95% CI 0.140–3.082) with no significant difference 
between the two groups (P>0.05, Table 7). 
Table 5. Comparison of the prevalence of adverse events 
between the two groups that was not related to treatment 
Adverse events 
cases (n) 
Group 
Yes No 
Total  
cases (n)
Prevalence 
(%) 
Treatment 4 56 60 6.67 
Control 6 48 54 11.11 
Total 10 104 114 8.77 
Note: Ȥ2 value (Pearson chi-square) 0.702, P=0.402>0.05. 
In the treatment group, one case related to adverse events 
of treatment was a toxic response to Ma Quan Zi: this 
response disappeared after dose reduction. 
Table 6. Comparison of ECG and laboratory results after treatment between the two groups 
Result became abnormal after treatment (n) Abnormal/normal (%) Index 
Treatment group (n=60) Control group (n=54) Treatment group (n=60) Control group (n=54)
ECG 0 0 0 (0/60) 0 (0/54)
WBC 0 0 0 (0/60) 0 (0/54)
RBC 0 0 0 (0/60) 0 (0/54)˅
HGB 0 0 0 (0/60) 0 (0/54)
PLT 0 0 0 (0/60) 0 (0/54)
RBCs in urine  3 4 5.00 (3/60) 7.41 (4/54)
Routine examination of 
stools 
0 0 0 (0/60) 0 (0/54)
ALT 0 0 0 (0/60) 0 (0/54)
AST 0 0 0 (0/60) 0 (0/54)
AKP 0 0 0 (0/60) 0 (0/54)
BUN 0 0 0 (0/60) 0 (0/54)
Scr 0 0 0 (0/60) 0 (0/54)
Notes: ECG=electrocardiography, WBC=white blood cell, RBC=red blood cell, HGB=hemoglobin, PLT=platelet, ALT=alanine 
aminotransferase, AST=aspartate aminotransferase, AKP=alkline phosphatase, BUN= blood urea nitrogen, and Scr=serum creatinine. 
Table 7. Comparison of the prevalence of normal RBCs 
in urine turning to abnormal RBCs between the two 
groups  
Normal turning to 
abnormal (n) 
Group 
Yes No 
Total (n) Prevalence 
(%) 
Treatment 3 57 60 5.00 
Control 4 50 54 7.41 
Total 7 107 114 6.14 
Notes: RR=0.658, Ȥ2 value (Pearson chi-square)=0.286, 
P=0.593>0.05. 
Drug Contents in Blood 
Strychnine and brucine could not be detected in the 
blood of the 10 patients who were randomly sampled 
each time. Blood samples possibly did not contain 
strychnine and brucine, or the concentrations of 
strychnine and brucine were below the lower limit of 
detection (100 ng/mL). Accumulation of strychnine and 
brucine in the blood of these patients was not found 
during administration and after administration for 8 
weeks. 
DISCUSSION 
Significance of Ma Qian Zi Individual Medication 
Ma Qian Zi (Semen Strychni) has been used clinically 
for ≈1000 years, so its therapeutic and adverse effects are 
known. It is regarded as a poisonous substance because 
the main components are strychnine and brucine. The 
median lethal dose (LD50) of strychnine and brucine as 
well as the kernel of nux vomica for intragastric 
administration in mice was found to be (in mg·kg–1) 3.27, 
233 and 235, respectively.14 The toxicity of strychnine is 
the largest. For an adult, the toxic amount is 5–10 mg, 
the lethal dose is 50–120 mg and, in human poisoning, 
the concentration of strychnine in the blood is 0.2
mg/mL.15 For strychnine, the commonly used dose for 
adults (6 mg) is close to the toxic dose. Hence, Ma Qian 
Zi (Semen Strychni) is the most suitable for individual 
medication. Hence, the dosage is incrementally increased 
to attain the best therapeutic effect while ensuring that 
toxicity is kept to a minimum. 
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Contents of Alkaloids after Processing and Joint 
Decocting of Ma Qian Zi 
Quality control of the processing of Ma Qian Zi (Semen 
Strychni) and joint decocting in the decoction as well as 
determination of the contents are key factors for ensuring 
the stability of alkaloid contents. 
Firstly, the quality of crude Ma Qian Zi should conform 
to the criteria in the Chinese Pharmacopeia.5 After single 
processing, the contents of strychnine and brucine also 
should conform to the criteria in the Chinese 
Pharmacopeia.5 In the present study, strychnine and 
brucine contents before and after processing of Ma Qian 
Zi (Semen Strychni) and after joint decocting in the 
decoction conformed to these requirements. 
For the quality control of decoction, standard rules of 
operation were established, and alkaloid contents in three 
batches of the decoctions added with 0.4, 0.6, 0.8, 1.0, 
and 1.2 g Ma Qian Zi (Semen Strychni) determined. The 
Chinese Pharmacopeia (2005 ed) stipulates that the upper 
limit of Ma Qian Zi in Wan (pills) and San (powder) is 
0.6 g. In the present study, the highest dose of Ma Qian 
Zi (Semen Strychni) in the decoction was 1.2 g, with 
strychnine representing 11.17 mg and brucine 7.44 mg, 
which was 83.86% and 155% of the highest dose in the 
Pharmacopeia, respectively (when the prepared Ma Qian 
Zi (Semen Strychni) was 0.6 g, the upper limit of 
strychnine was 13.32 mg and that of brucine was not less 
than 4.8 mg), thereby conforming to the stipulation in the 
Chinese Pharmacopeia. Therefore, the dose of prepared 
Ma Qian Zi (Semen Strychni) in the decoction was 
beyond the upper limit given in the Chinese 
Pharmacopeia, but the contents of alkaloids were within 
the range stipulated. Hence, the dose was safe. 
Nux-vomica Response 
The treatment dose of Ma Qian Zi (Semen Strychni) is 
close to its toxic dose. According to the literature,16–18
adverse reactions can be divided into mild, moderate and 
severe.17 In this classification, mild reactions are 
represented by fever, headache, dizziness, palpitation, 
nausea and vomiting, stomach ache, tongue numbness,
sweating, restlessness, blood-pressure increase, 
respiratory strengthening, mild muscular twitching, 
girdle sensation, and mild mental abnormality. Moderate 
adverse reactions include tonic spasm of entire muscles, 
and gaze shifting of both eyes. Severe adverse reactions 
include spasmodic contraction of respiratory muscles, 
convulsion, and dyspnea. 
Clinical research2,4 has shown that the highest dose of 
Ma Qian Zi results in the best therapeutic effect against 
the fluorosis of bone. A critical biochemical index for 
assessment of the improvement of fluorosis of bone is 
not available, so the nux-vomica response is used as 
basis of dose control of Ma Qian Zi. The present study 
demonstrated that dose regulation according to 
appearance or non-appearance of the nux-vomica 
response was safe. However, to ensure safety, the 
maximum dosage of Ma Qiann Zi (Semen Strychni) 
should be 1.2 g/day.  
Of the 60 cases who took the drug, 52 subjects did not 
have a nux-vomica response during treatment. Eight 
cases had a nux-vomica response once during treatment; 
for doses of 0.4, 0.5, 0.55, 0.75, 1.1, and 1.2 g/day, one 
case for each dose was noted; for 1.15 g/day, 2 cases 
were noted; 12-h later, the response disappeared. The 
dose was regulated to 1.2 g/day according to the 
therapeutic program. Another case had dizziness, as well 
as numbness in the right side of the face and limbs that 
was not alleviated after 1 day when the dose of Ma Qian 
Zi (Semen Strychni) was 1.1 g/day. After the dose of Ma 
Qian Zi was reduced to 1.05 g/day, the symptoms 
disappeared, and this dose was maintained until the end 
of the therapeutic course. After analyses, this subject was 
regarded as having a toxic reaction to Ma Qian Zi 
(Semen Strychni). 
Adverse Events 
Eighteen cases with adverse drug events were found in 
the two groups. After analyses of causality, 10 cases had 
general adverse events with no relationship to the 
therapeutic drug: respiratory tract infection (8 cases), 
fracture (1 case) and appendicitis (1 case). In the 
treatment group, there were 7 cases with suspicious
adverse events; all of them had occult blood in urine with 
abnormal laboratory results. The risk of an abnormal 
value in the treatment group was only 0.658-times that in 
the control group: this difference was not significantly 
different. Three months after suspension of drug 
administration, normality was restored. No abnormally 
was found at follow-up after 1–1.5 years. During 
administration of Guo’s Ma Qian Decoction, ECG, blood 
parameters, stool parameters, as well as hepatic and renal 
functions, did not show abnormalities. Toxicity was 
found in 1 case but the reaction disappeared when the 
dose was reduced. 
Determination of Drugs in Blood 
The concentration of alkaloids of Ma Qia Zi (Semen 
Strychni) was determined in 10 cases taking Guo’s Ma 
Qian Decoction to evaluate the concentrations of 
strychnine and brucine in blood so as to ensure safety of 
the medication. Concentrations of strychnine and brucine 
in the blood 1, 2, 3, 4, and 8 weeks after treatment were 
<100 ng/mL (the lowest detectable amount was 10 ng). 
This finding suggested that strychnine and brucine did 
not accumulate in blood during administration and after 
administration for 8 weeks. At the eighth week of 
administration, the dose of Ma Qian Zi (Semen Strychni) 
was 1.2 g/dose/day. 
In the present study, the lowest detectable amount for the 
alkaloids of Ma Qian Zi was lower than those in other 
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reports.19-21 Among those reports, the blood 
concentration in human poisoning was 2 μg/mL,15 which 
is 20-times that of the lowest amount detectable. 
According to the literature report, the commonly used 
dose of strychnine for adults is 6 mg, and the toxic 
amount of single daily administration is 5–10 mg. 
Calculation revealed that when the maximum dosage of 
prepared Ma Qian Zi (Semen Strychni) was 1.2 g/day 
(more than one-fold the maximum dosage stipulated in 
the Chinese Pharmacopeia), and that the strychnine 
content in the decoction was 11.17 mg. Because the 
decoction was taken in two portions, it was relatively 
safety. Also, strychnine and brucine were not detected in 
the plasma of patients.  
The key to Guo’s therapy is individual medication of Ma 
Qian Zi (Semen Strychni). The program involves 
progressively small increases in the drug dose, quality 
control of the raw materials, quality control of the 
decoction, analyses of adverse events, and monitoring of 
drug concentrations in the blood. The present study 
demonstrated that, in the treatment of moderate endemic 
fluorosis of bone with Guo’s therapy, individual 
regulation of Ma Quan Zi (Semen Strychni) dosage can 
ensure therapeutic effects1 and increase the safety of Ma 
Quan Zi (Semen Strychni) in decoction application. 
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